



## South Yorkshire ICB Position Statement on preference of SGLT2 inhibitors

**South Yorkshire recommends generic dapagliflozin 10 mg once daily as the first-line SGLT2 inhibitor for the cost-effective management of patients with type 2 diabetes (with or without chronic kidney disease) and/or heart failure, consistent with NHSE eligibility criteria\* and NICE guidance.**

### Background:

Over recent years, SGLT2 inhibitors have become integral in treating type 2 diabetes, heart failure and chronic kidney disease, demonstrating benefits in reducing cardiovascular death, hospitalisation for heart failure and progression of cardiorenal disease.

Since then, there have been important developments in both clinical guidance and market conditions.

- Shift in the treatment algorithm for diabetes management, with SGLT2 inhibitors now recommended earlier in the pathway for most patients with T2DM, particularly where cardiovascular risk or established heart failure is present.
- Expanded licensing across a broad range of indicators for some SGLT2 inhibitors (see table 1).
- The recent ruling invalidating the UK compound patent for Forxiga® (dapagliflozin) thereby enabling the entry of generic dapagliflozin into the supply chain at a significantly lower acquisition cost, with further reductions expected.

Given the comparable class-effect expectations for SGLT2 inhibitors, these developments provide a clear opportunity to maintain evidence-based outcomes while improving cost-effectiveness across both primary and secondary care.

This position is subject to the following provisos:

- **Management of chronic kidney disease (CKD)**- This position statement does not apply to the use of dapagliflozin in patients with chronic kidney disease (CKD) **without type 2 diabetes**. That indication remains patent-protected, under a supplementary patent effective from 17 September 2025.
- **Patient choice & clinical appropriateness**- Clinicians must ensure that therapy is tailored to the patient's clinical circumstances, comorbidities, preferences and tolerability. Alternative SGLT2 inhibitors may be used where clinically justified.

*Table 1 Licensed Indications for SGLT2 Inhibitors (UK – October 2025)*

Agent (Brand name)	Type 2 Diabetes Mellitus (T2DM)	Heart Failure with Reduced EF (HFrEF)	Heart Failure with Mildly Reduced / Preserved EF (HFmrEF / HFpEF)	Chronic Kidney Disease (CKD)

<b>Dapagliflozin (Generic*/Forxiga®)</b>	✓ Licensed (NICE TA288 / TA390/ NG28)	✓ Licensed (NICE TA679)	✓ Licensed (NICE TA902)	✓ Licensed (NICE TA1075)  See below re eligibility criteria
<b>Empagliflozin (Jardiance®)</b>	✓ Licensed (NICE TA336 / TA390/ NG28)	✓ Licensed (NICE TA773)	✓ Licensed (NICE TA929)	✓ Licensed (NICE TA942)
<b>Ertugliflozin (Steglatro®)</b>	✓ Licensed (NICE TA583 / NG28)	✗ Not licensed for HF	✗ Not licensed for HFpEF/HFmrEF	✗ Not licensed for CKD
<b>Canagliflozin (Invokana®)</b>	✓ Licensed (NICE TA315 / TA390/ NG28)	✗ Not licensed for HF	✗ Not licensed for HFpEF/HFmrEF	*Licensed for treatment of diabetic kidney disease as add-on to ACEi/ARB. There is no NICE TA to support use in the NHS, for this indication.

**\*NHSE eligibility criteria for generic dapagliflozin**

Eligibility for generic dapagliflozin (as of 17 Sept 2025)

<b>Patient Cohorts</b>	<b>Generic Dapagliflozin eligibility</b>
T2DM (may have other co-morbidities including CKD and HF)	Yes
Heart Failure	Yes
CKD without T2DM	No

AstraZeneca holds a second medical use patent for CKD in patients that do not have T2DM (active from 17 Sept), which is currently within the time limit for third parties to oppose the patent.

Date Approved by IMOC: December 2025 V1.0

Review date: December 2028

**References:**

1. NHS England. Letter to system- Optimising prescribing of SGLT2 inhibitors with generic dapagliflozin. Sent 06 October 2025
2. National Institute for Health and Care Excellence (NICE). *Chronic heart failure in adults: diagnosis and management* (NG106). Accessed 18 November 2025
3. NICE. *Dapagliflozin for treating chronic heart failure with reduced ejection fraction* (TA679). Accessed 18 November 2025
4. NICE. *Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction* (TA902). Accessed 18 November 2025
5. NICE. *Type 2 diabetes in adults: management* (NG28). Accessed 18 November 2025
6. NICE. *Dapagliflozin for treating chronic kidney disease* (TA1075). Accessed 18 November 2025
7. DAPA-HF Investigators, McMurray JJV et al., *Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction*. *N Engl J Med* 2019;381:1995-2008.
8. DELIVER Investigators, Solomon SD et al., *Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction*. *N Engl J Med* 2022;387:1089-1098.